Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 0 | 22 | 95 | 156 | 114,089 |
| Gross Profit | N/A | 22 | 95 | 156 | 114,089 |
| Operating Expenses | 209,315 | 273,221 | 327,832 | 335,692 | 294,281 |
| Operating Income | -209,315 | -273,199 | -327,737 | -335,536 | -180,192 |
| Interest Expense | 1,075 | 181 | 0 | 0 | 0 |
| Other Income | 19,504 | 16,233 | 472 | -4,878 | -1,859 |
| Pre-tax Income | -190,886 | -257,147 | -327,265 | -340,414 | -182,051 |
| Income Tax | N/A | 443 | N/A | N/A | N/A |
| Net Income Continuous | -190,886 | -257,590 | -327,265 | -340,414 | -182,051 |
| Net Income | $-190,886 | $-257,590 | $-327,265 | $-340,414 | $-182,051 |
| EPS Basic Total Ops | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| EPS Basic Continuous Ops | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| EPS Diluted Total Ops | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| EPS Diluted Continuous Ops | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.24 | -2.01 | -2.32 | -1.89 |
| EBITDA(a) | $-201,177 | $-267,908 | $-320,347 | $-318,350 | $-162,783 |